Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc shares valued at $170,467 were purchased by Watson David O. on Jan 22 ’26. At $21.77 per share, Watson David O. acquired 7,832 shares.
Also, Deschatelets Pascal purchased 5,928 shares, netting a total of over 129,025 in proceeds.
Before that, Sullivan Timothy Eugene had added 10,287 shares to its account. In a trade valued at $223,901, the Officer bought Apellis Pharmaceuticals Inc shares for $21.77 each.
As published in a research note from BofA Securities on January 21, 2026, Apellis Pharmaceuticals Inc [APLS] has been rated up from a Neutral to a Buy and the price target has been revised to $28. Analysts at Wolfe Research started covering the stock with ‘”a Peer perform”‘ outlook in a report released in early November. As of October 15, 2025, Wells Fargo has initiated its “an Overweight” rating for APLS. Earlier on September 26, 2025, Goldman downgraded its rating. Their new recommendation was “a Sell” for APLS stock which previously was a “a Neutral”.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] rose 5.01% to $22.0. The stock’s lowest price that day was $20.95, but it reached a high of $22.2399 in the same session. During the last five days, there has been a surge of approximately 8.21%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -26.98%.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 23412.0 shares to 16.12 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 16.1 million shares. A jump of 0.15% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.18 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.18.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 30.5 in the next 12 months, up nearly 45.58% from the previous closing price of $20.95. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 52 by 2026, with the lowest price target being 19. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2026. On May 09, 2025, Raymond James assigned a price target of “an Outperform” to the stock and downgraded coverage with a $52.
